Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH)
Complete Title: A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in
Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally
Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed
Following Treatment with Osimertinib (The SAVANNAH Study)
Trial Phase: II
Investigator: Christina Baik
This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib.
Keywords:
- Carcinoma
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Christina Baik
RG1005586
NCT03778229
A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in
Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally
Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed
Following Treatment with Osimertinib (The SAVANNAH Study)
Carcinoma